

Minutes of the **Somerset Prescribing Forum** held via Microsoft Teams, on **Wednesday, 14th July 2021**.

| | | |
|------------|--------------------------|---|
| Present: | Dr Andrew Tresidder (AT) | Chair, CCG GP Patient Safety Lead |
| | Steve DuBois (SDB) | Chief Pharmacist, Somerset NHSFT |
| | Shaun Green (SG) | Deputy Director of Clinical Effectiveness and Medicines Management, CCG |
| | Sam Morris (SM) | Medicines Manager, CCG |
| | Andrew Prowse (AP) | Chief Pharmacist and Controlled Drugs Accountable Officer, YDH NHS FT |
| | Caroline Taylor (CT) | Prescribing Technician, CCG |
| | Antony Zorzi | Chief Pharmacist, acute, Somerset NHSFT |
| | | |
| Apologies: | Dr Clare Barlow (CB) | Chair D&TC, Somerset NHSFT |
| | Dr Orla Dunn (OD) | Public Health Representative |
| | Jean Perry (JP) | Contracts Manager, NHS Somerset CCG |
| | Dr Carla Robinson (CR) | Public Health Registrar, Somerset County Council |

1 APOLOGIES FOR ABSENCE AND INTRODUCTIONS

Antony Zorzi introduced himself and was welcomed to the group as a member.

2 REGISTER OF MEMBERS' INTERESTS

- 2.1 The Somerset Prescribing Forum received the Register of Members' Interests relevant to its membership.

There were no further amendments to the Register.

The Somerset Prescribing Forum noted the Register of Members' Interests.

3 DECLARATIONS OF INTEREST RELATING TO ITEMS ON THE AGENDA

- 3.1 Under the CCG's arrangements for managing conflicts of interest, any member making a declaration of interest is able to participate in the discussion of the particular agenda item concerned, where appropriate, but is excluded from the decision-making and voting process if a vote is required. In these circumstances, there must be confirmation that the meeting remains quorate in order for voting to proceed. If a conflict of interest is declared by the Chairman, the agenda item in question would be chaired by a nominated member of the Somerset Prescribing Forum.

Antony Zorzi, Chief Pharmacist, acute, Somerset NHSFT declared he had a DOI with Pfizer Ltd.

4 MINUTES OF THE MEETING HELD ON 12th May 2021

4.1 The Minutes of the meeting held on 12th May were agreed as a correct record.

4.2 Review of action points

Most items were either complete or, on the agenda.

Item raised from May's meeting

[NG192] Caesarean birth - New

Current CCG policy has been reviewed & a recommendation made to retire the policy and move forward.

To review recent NICE guidance, refer to Dr Carla Robinson Action: CR

5 Matters Arising

5.1 Sativex[®] for the treatment of spasticity due to multiple sclerosis

Funding around this is still to be confirmed by Somerset NHSFT.
Commissioned for use by SCCG.

AP requested that Somerset NHSFT bring as a business case to enable YDH to be aware of cost pressures involved should Sativex[®] be used for YDH patients.

Bring back to Septembers meeting

Action: CT

6 Other Issues for Discussion

-None

7 Other Issues for Noting

7.1 Specialised Commissioning Circular SSC 2268 Specialised Commissioning Update July 2021 to September 2021

Highlighted for trusts to note and review accordingly

-Noted

8 Additional Communications for Noting

8.1 DHSC Monthly Supply Issues Update June & July

Shared with primary care colleagues for information

-Noted

8.2 Care homes - Vitamin D supplements - when government supply comes

to an end

Highlighted the message sent out to primary care, the view from CQC is care homes are required to meet their resident's nutritional needs.

Vitamin D supplements should be self-care and purchased over the counter.

-Noted

8.3 Medication Safety in Somerset

Raised regionally CQC are taking a more focused look at safety in primary care. Searches around high-risk drugs, MHRA alerts sent out and how primary care has responded. Over ordering / over prescribed.

This will bring very positive outcomes for patients around patient safety.

Somerset CCG support practices by providing Eclipse Live safety searches.

Going forward looking at these measures in other providers.

SM highlighted that patients are being discharged by trusts on clopidogrel and omeprazole, AZ feedback that this interaction has been visited several times within the trusts and would require a cultural change.

-Noted

8.4 Monitoring in Chronic Kidney disease

Eclipse data shows Somerset CCG has 3000+ patients on practice chronic kidney disease registers with no record of creatinine / eGFR in the last year.

The MM team recommend that this known group is considered for priority of recall for updated blood tests, alongside those on medication which needs dose adjustment based on renal function e.g. DOACs

It is also worth reminding patients that they are advised not to eat any meat in the 12 hours before having a blood test for creatinine/eGFR. Avoid delaying the despatch of blood samples to ensure that they are received and processed by the laboratory within 12 hours of venepuncture.

-Noted

9 Formulary Applications

9.1 Bempedoic acid

-Approved

SG to inform primary care of the change.

Action: SG

Change TLS from **RED** to **AMBER**, no written shared care document

Action: ZTW

9.2 Repatha® (Evolocumab), Amgen Limited

-Approved

Change TLS from **RED** to **AMBER**, no written shared care document

Action: ZTW

- 9.3 **Praluent® (Alirocumab), Sanofi**
 -Approved
 Change TLS from **RED** to **AMBER**, no written shared care document
Action: ZTW
- 9.4 **Tiogiva® (tiotropium) 18 microgram, inhalation powder, hard capsules**
 Indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
 -Approved.
 Add to formulary. **Action: Daniela Broughton**
 Add to inhaler VENN diagram. **Action: Caroline Taylor**
- 9.5 **Oxyact® (oxycodone hydrochloride) film-coated tablets 5mg, 10mg, 20mg**
 Indicated for the treatment of severe pain, which requires opioid analgesics to be adequately managed.
 -Approved
 Add to formulary. **Action: Daniela Broughton**
- 9.6 **Acopair® (tiotropium) 18 microgram, inhalation powder capsules with device, Viatris (30 capsules + device)**
 Indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
 -Approved
 Add to formulary. **Action: Daniela Broughton**
 Add to inhaler VENN diagram as preferred product **Action: Caroline Taylor**
- 9.7 **Luforbec® (beclometasone/formoterol) 100/6 microgram per actuation pressurised inhalation solution**
 Alternative to Fostair with same licensed indications and equivalent extra fine formulation
 -Approved
 Add to formulary. **Action: Daniela Broughton**
 Add to inhaler VENN diagram. **Action: Caroline Taylor**
- 9.8 **Strivit® D3 (colecalfiferol) soft capsules, 3,200IU, 20,000IU**
Indicated for the treatment of vitamin D deficiency (serum 25(OH)D <25 nmol/l).
 A few clinicians are prescribing high doses based on recommendations from secondary care.
 Strivit® D3 is a cost effective brand for the higher strength products.
 -Approved
 Add to formulary **Action: Daniela Broughton**

10 DTC decisions and other reports

10.1 Somerset NHS Foundation Trust Mental Health D&TC-

Last meeting 08/06/2021 – Minutes not received

SDB informed the group:

An audit is being carried out around reducing or stopping benzodiazepines.

Valproate audit is being finalised.

Discussions are ongoing with the Parkinson's disease service at MPH and the older person's mental health service regarding facilitating appropriate initiation of clozapine in Parkinson's patients.

10.2 YDH Medicines Committee

Last meeting 02/07/2021- Draft Minutes received

Points from May's meeting:

Discussed emergency steroid cards and it was recognised that they aren't fully compliant at present. Having difficulty ensuring that patients have their blue treatment card as well as their emergency card. This will be discussed at the next meeting.

Putting into place new adult passports for the safer use of insulin. The passports will include photos of the insulin so hopefully this will help with recognition and avoid incidents.

10.3 Somerset NHSFT D&TC

Last meeting 14/05/21 - Minutes received

-Nothing to note

10.4 Somerset Antimicrobial Stewardship Committee

Last meeting 13/05/2021- Minutes received

-It was noted the staffing issues at the moment

10.5 Somerset ICS Medicines Optimisation (SIMO) Committee

Last meeting 09/06/2021 - Minutes not received

-Nothing to note

10.6 RMOC function on SPS website

RMOC draft terms of reference: consultation - national consultation

RMOC shared care guidance: draft shared care protocols, consultation 1

SPF members can share internally and comment

Going forwards RMOC will be changing their terms of reference and will be looking for representation from every ICS. A discussion will need to be had around who attends on behalf of Somerset.

-Noted

Part 2 – Items for Information or Noting

11 NICE Guidance May, June and July

-Noted

12 NICE Technology Appraisals

12.1 [TA697] Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban - New

There is a requirement for trusts to hold stock and use if necessary.

Somerset NHSFT has been informed by manufacturer that they will replace expired stock.

YDH are keeping stock

-Approved

CCG Commissioned. Add to TLS RED Drug

Action: ZTW

12.2 [TA696] Tafamidis for treating transthyretin amyloidosis with cardiomyopathy - New

-Noted

Add to TLS Not recommended

Action: ZTW

12.3 [TA701] Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)

-Noted

Terminated Appraisal

Action: ZTW

12.4 [TA700] Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)

-Noted

Terminated Appraisal

Action: ZTW

12.5 [TA699] Ofatumumab for treating relapsing multiple sclerosis - New

-Approved

NHSE Commissioned. Add to TLS RED Drug

Action: ZTW

12.6 [TA698] Ravulizumab for treating paroxysmal nocturnal

haemoglobinuria

-Approved

NHSE Commissioned. Add to TLS RED Drug

Action: ZTW

- 12.7 **[TA704] Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies**

-Approved

NHSE Commissioned. Add to TLS RED Drug

Action: ZTW

- 12.8 **[TA703] Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)**

-Noted

Terminated Appraisal

Action: ZTW

- 12.9 **[TA702] Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)**

-Noted

Terminated Appraisal

Action: ZTW

- 12.10 **[TA705] Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer**

-Approved

NHSE Commissioned. Add to TLS RED drug

Action: ZTW

- 12.11 **[TA706] Ozanimod for treating relapsing–remitting multiple sclerosis – New**

Add to TLS Not Recommended

Action: ZTW

- 12.12 **[TA707] Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer**

-Approved

NHSE Commissioned. Add to TLS RED drug

Action: ZTW

- 12.13 **[TA710] Ravulizumab for treating atypical haemolytic uraemic syndrome**

-Approved

NHSE Commissioned. Add to TLS RED drug

Action: ZTW

- 12.14 **[TA709] Pembrolizumab for untreated metastatic colorectal cancer with**

high microsatellite instability or mismatch repair deficiency

-Approved

NHSE Commissioned. Add to TLS RED drug

Action: ZTW

12.15 **[TA708] Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis**

-Approved

CCG Commissioned. Add to TLS AMBER drug

Action: ZTW

12.16 **[TA711] Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs**

-Approved

CCG Commissioned. Add to TLS RED drug.

Action: ZTW

12.17 **[TA249] Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation – Updated July 2021**

-Noted

Check formulary and guidance are in line with updated advice

Action: Steve Moore

Add link to NICE update to TLS

Action: ZTW

12.18 **[TA256] Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation – Updated July 2021**

-Noted

Check formulary and guidance are in line with updated advice

Action: Steve Moore

Add link to NICE update to TLS

Action: ZTW

12.19 **[TA275] Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation – Update July 2021**

-Noted

Check formulary and guidance are in line with updated advice

Action: Steve Moore

Add link to NICE update to TLS

Action: ZTW

12.20 **[TA355] Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation – Update July 2021**

-Noted

Check formulary and guidance are in line with updated advice

Action: Steve Moore

Add link to NICE update to TLS

Action: ZTW

- 12.21 **[TA712] Enzalutamide for treating hormone-sensitive metastatic prostate cancer**
 -Approved
NHSE Commissioned. Add to TLS RED drug **Action: ZTW**
- 12.22 **[TA713]Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy**
 -Approved
NHSE Commissioned. Add to TLS RED drug **Action: ZTW**
- 12.23 **[TA714]Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)**
 -Noted
Terminated Appraisal **Action: ZTW**
- 12.24 **[TA715] Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed - New**
 -Approved
CCG Commissioned. Add to TLS RED drug **Action: ZTW**
- 13 NICE Clinical Guidance**
- 13.1 **[CG137] Epilepsies: diagnosis and management - Update updated MHRA safety advice on antiepileptic drugs in pregnancy.**
 -Noted
- 13.2 **[CG150] Headaches in over 12s: diagnosis and management - Update**
 -Noted
Check formulary and guidance are in line with updated advice
Action: Helen Spry
- 13.3 **[CG138] Patient experience in adult NHS services: improving the experience of care for people using adult NHS services - Update**
 -Noted
- 13.4 **[CG142] Autism spectrum disorder in adults: diagnosis and management -Update**
 -SG has raised with commissioners

-Noted

13.5 **[CG170] Autism spectrum disorder in under 19s: support and management -**

-Noted

13.6 **[NG88] Heavy menstrual bleeding: assessment and management - Update**

MHRA safety advice on the risk of serious liver injury with ulipristal acetate (Esmya).

-Noted

13.7 **[NG191] COVID-19 rapid guideline: managing COVID-19 - Update**

-Noted

13.8 **[NG196] Atrial fibrillation: diagnosis and management - Update**

-Noted

Check formulary and guidance are in line with updated advice

Action: Steve Moore

13.9 **[NG197] Shared decision making - New**

-Noted

13.10 **[NG198] Acne vulgaris: management - New**

Somerset CCG Formulary has been updated in line with guidance.

Pregnancy and breast-feeding in process of being updated

Antimicrobial guidance in process of being updated.

-Noted

14 Specialist Commissioning

14.1 **NHS England: May 2021 CPAG Decision statement**

New recommendations made

-Noted

15 Risk review and management

15.1 **Risk review and Management - COVID 19**

There is limited information regards the booster campaign. After discussion the group agreed to bring update back to September's meeting.

Add to Septembers agenda

Action: CT

16 Safety Items, NPSA Alerts and Signals

- 16.1 **MHRA Drug Safety Update May, June & July**
-Noted
- 16.2 **NPSA Alert: Urgent assessment/treatment following ingestion of 'super strong' magnets**
-Noted
- 16.3 **Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products**
-Noted
- 16.4 **Atezolizumab (Tecentriq ▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)**
-Noted
- 16.5 **CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases**
-Noted
- 16.6 **Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years**
Somerset CCG PGD and antimicrobial guidelines have been updated
-Noted
- 16.7 **Herbal and homeopathic medicines: reminder to be vigilant for suspected adverse reactions and to report them to the Yellow Card scheme**
Please see link, to a very good study about awareness generally of the Yellow Card scheme.
<https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14726>
-Noted
- 16.8 **Oral retinoid medicines (isotretinoin▼, alitretinoin ▼, and acitretin▼): temporary monitoring advice during coronavirus (COVID-19) pandemic**
Prescribing by primary care due to travelling restrictions during COVID, is being repatriated back to trusts
-Noted
- 17 **BNF Changes**
17.1 **BNF Update May & June**

-Noted

18 Any Other Business

18.1 SG informed the group he is the designated flu lead.

18.2 Discussion around potentially going forwards sharing one formulary platform. AZ and AP to send SG details of the current formulary page on their intranet

To discuss with IT and establish if CCG IT compatible.

Bring back to next meeting

Action: CT

18.3 Should CB wish to bring back any specific items included in the NICE guidance section, group happy to discuss.

18.4 Dr Andrew Tresidder sent his apologies for September's meeting

DATE OF NEXT MEETINGS

8th September 2021

10th November 2021

MEETING DATES FOR 2022

19th January

16th March

11th May

13th July

14th September

16th November